Clinical Trials
32 trialsPembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
M.D. Anderson Cancer Center
Pembrolizumab in Treating Patients With Malignant Mesothelioma
University of Chicago
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma
Memorial Sloan Kettering Cancer Center
MESO-PRIME
Royal Marsden NHS Foundation Trust
PEMBIB
Gustave Roussy, Cancer Campus, Grand Paris
Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
University of Pittsburgh
CHIMERA
Istituto Oncologico Veneto IRCCS
Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies
University of Kansas Medical Center
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
Abramson Cancer Center at Penn Medicine
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Memorial Sloan Kettering Cancer Center
A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies
Providence Health & Services
Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors
University of Chicago
PENINSULA
Hyogo Medical University
Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers
M.D. Anderson Cancer Center
Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers
M.D. Anderson Cancer Center
PEMMELA
The Netherlands Cancer Institute
MESOVAX
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
University of Chicago
Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors
Baptist Health South Florida
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
Beijing Friendship Hospital
MiST
University of Leicester
Special Combination of OBP-301 and Pembrolizumab
National Cancer Center Hospital East
PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
UVA-AM-001
University of Virginia
Pembrolizumab + Defactinib In Pleural Mesothelioma
Dana-Farber Cancer Institute
Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors
Fuda Cancer Hospital, Guangzhou
Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)
NHS Greater Glasgow and Clyde
A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
Case Comprehensive Cancer Center